These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21677480)

  • 1. [Second-line treatment of advanced renal cell carcinoma after first-line targeted therapy].
    Tomita Y
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):907-10. PubMed ID: 21677480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma.
    Yang CH; Chuang CK; Hsieh JJ; Chang JW
    Expert Opin Drug Saf; 2010 May; 9(3):459-70. PubMed ID: 20113155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular targeted therapy for advanced renal cell carcinoma].
    Kanayama H
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1208-13. PubMed ID: 20647700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
    Oudard S; Elaidi RT
    Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy of renal cell cancer.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential use of targeted agents in the treatment of renal cell carcinoma.
    Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temsirolimus in renal cell carcinoma.
    Otto T; Eimer C; Gerullis H
    Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current systemic management of metastatic renal cell carcinoma - first line and second line therapy.
    Wright I; Kapoor A
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):211-21. PubMed ID: 21725244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
    Kapoor A; Figlin RA
    Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence.
    Tonini G; Fratto ME; Imperatori M; Pantano F; Vincenzi B; Santini D
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):921-30. PubMed ID: 21707289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
    Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
    Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
    Sonpavde G; Choueiri TK; Escudier B; Ficarra V; Hutson TE; Mulders PF; Patard JJ; Rini BI; Staehler M; Sternberg CN; Stief CG
    Eur Urol; 2012 Feb; 61(2):307-16. PubMed ID: 22055147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Renal cell carcinoma-response criteria of molecular targeted therapy and the timing of sequential drugs in patients with advanced renal cell carcinoma].
    Shinohara N
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1462-6. PubMed ID: 23064056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients.
    Ueda T; Imamura Y; Komaru A; Fukasawa S; Sazuka T; Suyama T; Naya Y; Nihei N; Ichikawa T; Maruoka M
    Int J Urol; 2010 Sep; 17(9):811-5. PubMed ID: 20649824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on novel agents in renal cell carcinoma.
    Tamaskar I; Pili R
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1817-27. PubMed ID: 19954293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.
    Bex A; Jonasch E; Kirkali Z; Mejean A; Mulders P; Oudard S; Patard JJ; Powles T; van Poppel H; Wood CG
    Eur Urol; 2010 Dec; 58(6):819-28. PubMed ID: 20828919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib for the treatment of advanced renal cell carcinoma.
    Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
    Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the medical treatment of metastatic renal cell carcinoma.
    Ravaud A; Wallerand H; Culine S; Bernhard JC; Fergelot P; Bensalah K; Patard JJ
    Eur Urol; 2008 Aug; 54(2):315-25. PubMed ID: 18485581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.